VivoSeq
Infectious Disease

Sepsis

233

Pipeline Programs↗

69

Active Trials↗

74

Companies Involved↗

Sepsis is a highly competitive landscape with 233 programs across 74 companies. The most active players are Enlivex Therapeutics Ltd., Regeneron, Neurim Pharmaceuticals Ltd.. 54 therapies are approved with 52 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

84/100

Pipeline Velocity

50/100

Mech. Concentration

9/100

Completion Rate

82/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

E

Enlivex Therapeutics Ltd.

1 program

Phase 1Regeneron logo

Regeneron

1 program

Phase 1N

Neurim Pharmaceuticals Ltd.

1 program

Phase 1A

Agouron Pharmaceuticals

1 program

Phase 1I

Iperboreal Pharma Srl

1 program

Phase 1M

Matisse Pharmaceuticals

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical48

Esmolol

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Linezolid

Pfizer

Paricalcitol

AbbVie

Imipenem

Pfizer

Norepinephrine

General Hospital of Ningxia Medical University

Phase 118

Ketamine

Aultman Health Foundation

Alirocumab

Regeneron

Melatonin

Neurim Pharmaceuticals Ltd.

Nelfinavir

Agouron Pharmaceuticals

Dexamethasone

Aspen Global Incorporated

Phase 261

Chlorhexidine Gluconate

Medline Industries

Anakinra

Swedish Orphan Biovitrum

Zinc Sulfate

Fakultas Kedokteran Universitas Indonesia

Baricitinib

Eli Lilly

BCG Vaccine

Gynecologic Oncology Group

Phase 352

Ulinastatin

Techpool Bio-Pharma Co., Ltd.

Thiamine

Universiti Kebangsaan Malaysia Medical Centre

Metformin

EMD Serono

Irbesartan

Sanofi

Hydrocortisone

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved54

Ceftriaxone

Conrado Roberto Hoffmann Filho

Tranexamic Acid

Amring

Acetaminophen

Kenvue Brands

Vasopressin

Aultman Health Foundation

Meropenem

B. Braun Medical Inc.

Analysis

Modality Breakdown

95%

Small molecule

267 of 282 classified programs — the dominant modality here.

5%ALL OTHERSProtein / enzyme62%Monoclonal antibody52%Vaccine2<1%Peptide1<1%Cell therapy1<1%

Small molecule leads; the ring shows all 282 classified programs, each share of the total. Modality classified for 99% of 309 pipeline programs.

Analysis

Trial Status

292

clinical trials

Completed149 · 51%
Unknown status42 · 14%
Recruiting38 · 13%
Not yet recruiting24 · 8%
Terminated19 · 7%
Withdrawn10 · 3%
Other10 · 3%

Clinical Trials

Trial Activity

292 trials

Early Administration of Norepinephrine in Sepsis
Recruiting·TTunis University·Phase 4·NCT05836272·200 enrolled
Metformin and Lactoferrin in Sepsis in Icu
Recruiting·TTanta University·Phase 2/3·NCT06181422·60 enrolled
Observational Study About the Use of Perfusion Index to Use Vasopressor in Sepsis
Recruiting·—·N/A·NCT06860438·40 enrolled
Human Umbilical Cord Mesenchymal Stem Cells Treatment in Sepsis
Recruiting·—·Phase 1·NCT06882811·180 enrolled
MID-STEP (MIDodrine for Sepsis Treatment and Early vasoPressor Weaning) Trial
Recruiting·MMayo Clinic·Phase 2·NCT06319248·308 enrolled
Volume Kinetics of Fluid Resuscitation in Early Sepsis
Recruiting·IInstitutul de Urgenţă pentru Boli Cardiovasculare Prof.Dr. C.C. Iliescu·N/A·NCT06499701·15 enrolled
Longitudinal Evolution of Biomarkers of Dysautonomia and Inflammation During Sepsis in Children
Recruiting·—·N/A·NCT05807555·60 enrolled
Early Vasopressors in Sepsis
Recruiting·NNHS Greater Glasgow and Clyde·Phase 3·NCT05179499·1,006 enrolled
Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT)
Recruiting·HHellenic Institute for the Study of Sepsis·Phase 3·NCT06294600·330 enrolled
Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial
Recruiting·UUniversity of Minnesota·Phase 2·NCT05758246·220 enrolled
Evaluation of the Performance of the IDBIORIV Method in Pathogen Identification and Antibiotic Susceptibility Testing in Patients With Sepsis
Recruiting·HHospices Civils de Lyon·N/A·NCT06219135·1,372 enrolled
Nasal Antisepsis for C. Auris Prevention
Recruiting·—·Phase 4·NCT06282510·120 enrolled
Beta-Lactam Antibiotics InitiaL ExpoSure OptimisEd in CriticallY Ill Patients with SEpsis
Recruiting·EErasmus Medical Center·Phase 4·NCT06766461·980 enrolled
Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS
Recruiting·NNationwide Children's Hospital·Phase 2/3·NCT05267821·500 enrolled
Efficacy of SGLT2 Inhibitors in Adults With Sepsis
Recruiting·HHospital Authority, Hong Kong·N/A·NCT06473844·60 enrolled
Page 1 of 20

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)